Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Beneficial Effects of Okra (Abelmoschus Esculentus L.) Consumption on Anthropometric Measures, Blood Pressure, Glycaemic Control, Lipid Profile and Liver Function Tests in Randomised Controlled Trials: A Grade-Assessed Systematic Review and Dose-Response Meta-Analysis Publisher Pubmed



Jafari A1, 2 ; Mardani H3 ; Parsi Nezhad B4 ; Alaghi A2 ; Sahebkar A5, 6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Department of Community Nutrition, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Student Research Committee, Department of Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  4. 4. Student Research Committee, Department of Nutrition, School of Health, Golestan University of Medical Sciences, Gorgan, Iran
  5. 5. Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
  6. 6. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Source: British Journal of Nutrition Published:2025


Abstract

This review aimed to assess the impact of okra (Abelmoschus esculentus L.) consumption on CVD risk factors. Relevant studies were identified through electronic searches of databases, including PubMed, Scopus, Web of Science, CENTRAL and EMBASE, up to January 2025. Twelve trials involving 770 participants with interventions ranging from 2 to 12 weeks and doses varying from 125 to 40 000 mg/d were included. Okra supplementation significantly reduced BMI (standardised mean difference (SMD) = -0·70; 95 % CI -1·23, -0·16; P = 0·011), fat mass (SMD = -0·74; 95 % CI -1·13, -0·36; P < 0·001), hip circumference (SMD = -0·85; 95 % CI -1·41, -0·28; P = 0·003), weight (SMD = -0·77; 95 % CI -1·42, -0·11; P = 0·022), fasting insulin (SMD = -0·35; 95 % CI -0·63, -0·07; P = 0·013), fasting plasma glucose (SMD = -1·07; 95 % CI -1·75, -0·38; P = 0·002), HbA1c (SMD = -0·38; 95 % CI -0·71, -0·05; P = 0·023), homeostatic model assessment of insulin resistance (SMD = -0·56; 95 % CI -0·84, -0·29; P < 0·001), LDL-cholesterol (SMD = -0·32; 95 % CI -0·52, -0·11; P = 0·003), total cholesterol (SMD = -0·45; 95 % CI -0·74, -0·16; P = 0·003) and aspartate aminotransferase (SMD = -0·45; 95 % CI -0·73, -0·17; P = 0·002). Okra supplementation demonstrated significant benefits in improving anthropometric measures, glycaemic control, lipid profiles and liver function tests, suggesting its potential as an adjunct therapy for improving CVD risk factors. © The Author(s), 2025. Published by Cambridge University Press on behalf of The Nutrition Society.
Experts (# of related papers)
Other Related Docs